Cancer Convergence Seminar Series – Engineering and Physical Sciences to Advance Cancer Research (Bevan and Ladame) | Events

In this webinar series brought by the UK Cancer Research Convergence Science Center at Imperial College London and the Institute of Cancer Research, London, researchers from both organizations will discuss the key challenges facing cancer research and the opportunities for new convergent scientific approaches to address them. Join us to explore how new approaches and technologies could shed light on unsolved problems in cancer biology, to innovate new ways to address cancer challenges and bring pioneering treatments to cancer patients faster.

Hosted by the Scientific Director of the Convergence Science Center Professor Axel Behrensthe series aims to support the Center’s mission to facilitate collaboration between traditionally separate and distinct disciplines.

Please join us on thursday 30e June, from 15.00-16.00for a conference of:

Professor Charlotte Bevan – Surgery & Cancer Department, imperial college london

“Cell-free nucleic acid biomarkers for prostate cancer: two steps forward, one step back?”

Prostate cancer is the most commonly diagnosed male cancer and the second leading cause of cancer death for men in the UK. Localized disease may remain clinically insignificant, while some tumors progress to life-threatening, treatment-resistant disease. It is currently not possible to reliably predict the evolution of a tumour. We will discuss the potential uses of circulating microRNAs and cell-free DNA in diagnosis and/or prognosis and their potential for use as minimally invasive biomarkers in prostate cancer.

&

Doctor Sylvain Ladame – Department of Bioengineering, imperial college london

“Platform technologies for cancer diagnosis based on the detection of cell-free nucleic acids in liquid biopsies”

Circulating cell-free nucleic acids (ccfNA) in body fluids have recently emerged as clinically useful and minimally invasive biomarkers for a wide range of cancers. However, their low natural abundance and high sequence homology make these biomarkers particularly difficult to detect, especially when using inexpensive point-of-care devices. We will report on the design, engineering, and successful preclinical testing of new platform technologies (lateral flow assay, hydrogel-filled nanopore, microneedle patch) for the amplification-free detection of endogenous ccfNAs from the blood plasma or skin interstitial fluid.

To join us in person:

The Cancer Research UK Convergence Science Center is located in the Roderic Hill Building (5th Floor – South Kensington Campus, SW7 2AZ). Please use the street entrance on Prince Consort Road where you will be further guided to our seminar room. Everyone is welcome!

To receive information on how to access this event via Zoom, please email [email protected]

About the speakers:

Professor Charlotte Bevan

Professor Bevan joined Imperial College as a Lecturer in 1999. Previously, she completed her BSc (Natural Sciences) and PhD at the University of Cambridge before moving on to postdoctoral work at the London Research Institute ( now the Crick). His research career has always focused on the mechanisms of androgen signaling and the consequences of its deregulation; it started during his PhD on Androgen Insensitivity Syndrome, a pediatric disease, and is now firmly focused on steroid signaling in endocrine cancer, specifically prostate cancer. This has more recently led to major research interest in microRNAs (and certain other nucleic acids): their impacts on androgen signaling, their role in prostate cancer, their therapeutic potential and utility as diagnostic biomarkers, prognostic and predictive.

Doctor Sylvain Ladame

Dr Sylvain Ladame joined the Department of Bioengineering at Imperial College London in 2010 and is now a lecturer in biosensor development. Previously, he spent five years as a postdoctoral researcher at the University of Cambridge in the group of Sir Prof Shankar Balasubramanian (2001-2006) before starting his independent academic career at the CNRS within the Institute of Sciences and of supramolecular engineering from Strasbourg, French (2006-2010). Dr. Ladame has been interested in the chemical biology of nucleic acids for over 20 years and since joining Imperial College London he has focused his research on the development of platform technologies and medical devices based on the detection of circulating cell-free nucleic acids in liquid biopsies. Major applications include the development of predictive tests for premature birth (prenatal testing) and new screening tools for a range of cancer types including prostate, breast, endometrial and skin.

Registration

To receive information on access to this event, please send an e-mail [email protected]

Note: This webinar is exclusively for colleagues from the Institute of Cancer Research, Imperial College London, Royal Marsden Hospital and Imperial College Healthcare.

About Stephen Arrington

Check Also

Wexford teenagers attend international youth leadership seminar

A group of teenagers from County Wexford were among 250 young people from around the …